Cell autonomous regulation of herpes and influenza virus infection by the circadian clock by Edgar, Rachel S et al.
 1 
Cell autonomous regulation of herpes  
and influenza virus infection by the 
circadian clock 
 
 
 
 
Rachel S. Edgara, Alessandra Stangherlina, Andras D. Nagya,1, Michael P. Nicollb,2, 
Stacey Efstathioub,2, John S. O’Neilla,3, Akhilesh B. Reddya 
 
a University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of 
Metabolic Science, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK. 
 
b Division of Virology, Department of Pathology, Tennis Court Road, Cambridge, CB2 1QP, UK. 
 
 
 
 
 
Correspondence: areddy@cantab.net  
1 
  
                                                
1 Institute affiliation: University of Pecs Medical School, Department of Anatomy, Pecs, Hungary. 
2 Present address: National Institute for Biological Standards and Control, Blanche Lane, South 
Mimms, Potters Bar, Hertfordshire, EN6 3QG. 
3 Present address: MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 
0QH, UK. 
 
 2 
Abstract 
Viruses are intracellular pathogens that hijack host cell machinery and biosynthetic resources 
to replicate. Rather than being constant, host physiology is rhythmic and undergoes circadian 
(24 hour) oscillation in a variety of virus-relevant pathways. Whether these daily rhythms 
impact on viral replication is not known. Here we show that the time of day at which the host 
is infected regulates virus progression in live mice and in individual cells. Furthermore, we 
demonstrate that herpes and influenza A virus infections are enhanced when host circadian 
rhythms are abolished by disrupting the key clock gene Bmal1. Intracellular trafficking, 
biosynthetic processes, protein synthesis and chromatin assembly all contribute to circadian 
regulation of virus infection. Moreover, herpesviruses differentially target components of the 
molecular circadian clockwork Our work thus demonstrates that viruses exploit the 
clockwork for their own gain, and that the clock therefore represents a novel target for 
modulating viral replication that extends beyond a single family of these important 
pathogens. 
 
 
 
Significance  
The circadian clock coordinates our physiology. Circadian disruption, as occurs during shift 
work, increases the risk of chronic diseases. For infectious diseases, circadian regulation of 
systemic immunity is thought to underpin ‘time-of-day’ differences in the response to 
extracellular pathogens. However, circadian rhythms are cell-autonomous and their 
interaction with intracellular pathogens, such as viruses, has not been investigated. We 
demonstrate that the time of day when virus infection occurs has a major impact on disease 
progression not only in animals but also using cellular models, highlighting that the cellular 
circadian clock plays a key role in this phenomenon. Disruption of the clock leads to 
increased virus replication and dissemination, indicating that severity of acute infections can 
be influenced by circadian timekeeping.   
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Introduction 
Diverse behavioral, physiological and cellular processes exhibit daily (circadian) rhythms, 
which persist in the absence of external timing cues (1). Cell-autonomous biological clocks 
drive circadian rhythms observed at the whole organism level, enabling adaptation to the 24-
hour solar cycle produced by the Earth’s rotation (2). At the molecular level, circadian 
oscillations are thought to be generated by genetic feedback loops involving the activating 
transcription factors BMAL1 (ARNTL; Mop3), NPAS and CLOCK. These drive 
transcription of repressor proteins CRYPTOCHROME1/2 (CRY1/2) and PERIOD1/2 
(PER1/2) that feedback to repress their own transcription, with post-translational processes 
and metabolic activity making an additional contribution to host timekeeping (3-5).  
 Circadian clocks confer competitive advantage to organisms and their disruption 
incurs fitness costs. They influence many aspects of human health and disease including 
sleep/wake cycles and immune function (6-8). Indeed, numerous components of the innate 
and adaptive immune response are regulated by the circadian clock. The immune response 
undergoes regeneration and repair as the host transitions to the resting phase of its daily 
cycle, whereas it is primed for pathogen attack at the onset of the active phase (6, 7). 
Although changes in host responses to bacterial endotoxin or infection at different times of 
day have been reported (9, 10), the influence of host circadian clocks on the progression of 
viral disease is not known. Here, we demonstrate dynamic host-virus interactions over the 24 
h day, and show that disrupting the circadian clockwork genetically augments virus 
replication in mice and cell models. 
  
Results  
Time of day influences virus infection 
Since viruses are obligate intracellular pathogens, they require a host organism in order to 
proliferate. Over the course of a day, viruses may encounter host environments that are more 
or less conducive to replication and dissemination (6, 11-13). We therefore hypothesized that 
the time of day when infection occurs would influence viral replication. To test this, we 
infected wild type (WT) mice intranasally with a recombinant luciferase-expressing virus, 
Murid Herpesvirus 4 (M3:luc MuHV-4), at two times of day (Fig. 1A; Fig. S1A). As a rodent 
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pathogen, this virus elicits natural host immune responses and implements evasion strategies 
in laboratory mice (14, 15), which allow it to establish a latent (or quiescent) infection after 
primary infection. When WT mice were infected at the onset of their resting phase (Zeitgeber 
Time 0 (ZT0); “lights on”), virus replication in the nose was 10-fold higher than in mice 
infected just before they entered their active phase at ZT10 (Fig. 1A). This was under clock 
control because when we infected Bmal1–/– mice, which have no overt circadian rhythms (3) 
(Fig. 1B; Fig. S1B), no difference was seen between groups infected at different times. 
Furthermore, Bmal1–/– mice exhibited high levels of MuHV-4 infection when inoculated at 
either time of day (Fig. S1C-F). Together, these results indicate that the timing of infection in 
relation the circadian cycle has a major impact on herpesvirus pathogenesis.  
 
Virus infection is enhanced in Bmal1–/– mice 
Given that infection of Bmal1–/– mice resulted in high levels of virus replication in vivo (Fig. 
S1D and F), we hypothesized that its role in clock function was important in regulating virus 
propagation. We therefore longitudinally tracked M3:luc MuHV-4 infection in WT and 
Bmal1–/– mice, introducing infection into the nose at ZT7 – the time at which BMAL1 is 
maximally active at genomic sites in peripheral tissues (11),(16, 17). Strikingly, virus 
replication increased > 3-fold at days 5-7 in Bmal1–/– mice compared to WT mice (Fig. 2A 
and B; Fig. S2A). We saw a similar pattern when the acute infection spread to the superficial 
cervical lymph nodes (SCLN) (Fig. 2A and B). By contrast, latent infection was established 
to a similar extent in WT and Bmal1–/– mice (Fig. S2B and C).  
To exclude the possibility that elevated infection levels were specific to MuHV-4, we 
infected mice with a different herpesvirus, Herpes Simplex Virus 1 (HSV-1), by scarification 
of the left ear. We again tracked the progression and extent of HSV-1 infection using a 
recombinant virus that encoded luciferase, this time under the control of the cytomegalovirus 
immediate early gene promoter (CMV:luc HSV-1) (18). Acute HSV-1 infection was 
significantly enhanced in arrhythmic Bmal1–/– mice (Fig. 2C and D; Fig. S2D and E), as seen 
with MuHV-4. As infection progressed, Bmal1–/– mice failed to contain HSV-1 spread, which 
disseminated across the head to the right ear (Fig. 2C and D). Analogous to MuHV-4, 
although acute infection was more severe when circadian rhythms were disrupted, latent 
infection was established to a similar extent in both genotypes; an apparent trend towards 
higher numbers of latent viral genomes in Bmal1–/– mice was noted, although this did not 
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reach statistical significance (Fig. S2F), suggesting that the circadian clock principally 
modulates primary infection in vivo. 
 
Clock-regulated virus replication in cells  
A more vigorous immune response to incoming virus at the onset of the active (dark) period 
could contribute to less MuHV-4 infection at ZT10 in vivo. We therefore investigated virus 
replication at different circadian times in synchronized cell models, which display robust 24 h 
oscillations but are not subject to systemic immune regulation (Fig. 3A). In order to study the 
effect of the cellular clock, we used confluent monolayers in which there were limited 
numbers of dividing cells, and no detectable circadian oscillation in cell cycle activity post-
synchronization (Fig. S3; Movie S1). We employed real-time bioluminescence recording 
systems to monitor both M3:luc MuHV-4 replication kinetics with high temporal resolution, 
and the amount of virus replication as total bioluminescence, which correlated with infectious 
particle production (Fig. 3B; Fig. S4A-C). Strikingly, when cell populations were infected 
with MuHV4 at different times in vitro, the time-of-day effect on infection observed in mice 
was recapitulated (Fig. 3C and D): Total bioluminescence is significantly increased in cells 
infected during the rising phase of Bmal1 expression (CT18–24, indicated by open 
arrowheads) compared to cells infected during decline of Bmal1 expression (CT30–36, 
indicated by solid arrowheads)(Fig. 3C). Furthermore, infection of cells with MuHV-4 at 
different times significantly altered the rate of virus replication (Fig. 3D). The entire kinetic 
profile of infection depended on the circadian phase that the virus encounters, such that 
slower initial replication rates are associated with prolonged viral gene expression (Fig. 3D; 
Fig. S4D; Pearson’s r = 0.999 (1st cycle) or r = 0.982 (2nd cycle), P < 0.01).  
Moreover, in agreement with our in vivo observations, MuHV-4 infection was 
significantly increased in primary Bmal1–/– fibroblasts compared to WT cells (Fig. 4A and B; 
Movie S2). When synchronized WT and Bmal1–/– fibroblasts were infected at different 
circadian times (Fig. S5A; CT of infection indicated by open and solid arrowheads), the time-
of-day effect on MuHV-4 infection observed in WT cells was abolished in those from Bmal1–
/– mice (Fig. 4C; Fig. S5B). Additionally, HSV-1 replication is significantly enhanced in 
Bmal1–/– cells compared to WT cells (Fig. 4D and E; Movie S3). Thus, the cellular circadian 
clock exerts a major effect on herpesvirus infection, indicating that our observations in live 
mice do not simply result from circadian modulation of immune cell function. 
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Given that cellular circadian rhythms impact on virus replication, we speculated that 
herpesviruses may manipulate the molecular clockwork during infection. To assess this, we 
infected mouse NIH3T3 cells expressing luciferase under the control of the Bmal1 promoter 
(Bmal1:luciferase or Bmal:luc) with MuHV-4 at different circadian times (Fig. 5A; Fig. 
S6A). Interestingly, MuHV-4 acutely induced Bmal1 expression from ~6 h post-infection, 
irrespective of the circadian phase at which the cells were infected (one-way ANOVA: peak 
Bmal1:luc, P < 0.0001). The subsequent pattern of cellular circadian rhythms during viral 
infection depended on the time at which cells were infected. Virus-mediated Bmal1 induction 
during the endogenous fall in Bmal1 transcription generated a Bmal1 peak and disrupted 
circadian reporter expression (infection at CT18-24, indicated by open arrowhead in Fig. 5A; 
Fig. S5). In contrast, viral induction at other times (infection at CT30-36; indicated by solid 
arrowhead in Fig. 5A) enhanced the usual rise in Bmal1 transcription, and cellular rhythms 
remained robust for three cycles afterwards (Fig. S6A). These findings strongly suggest that 
induction of Bmal1 expression by herpesviruses has different consequences for clock 
function depending on when in the circadian cycle infection occurs. 
Analogous to the arrhythmic Bmal1–/– in vivo and cellular models, enhanced viral 
replication is observed in cells infected at circadian times when endogenous circadian 
rhythms are subsequently disrupted (see Fig. 3D and E, and Fig. 5A and B; indicated by open 
arrowheads). In mouse peripheral tissues that support herpesvirus replication, cellular CT24 
corresponds to onset of the rest (light) period (19-21), where rapid, higher levels of 
replication initially would maximize the chance of transmission during the subsequent active 
(dark) period 12-24 h later. Cellular CT36 corresponds to the onset of the active period, when 
slower, lower levels of replication would permit efficient transmission in the following active 
period 24-36 h later, and perhaps reduce detection at a time when the immune system is 
primed for pathogen attack.  
Critically, expression of repressive clock genes, such as mCryptochrome1 (mCry1) 
and mPeriod2 (mPer2), was not induced during viral infection (Fig. 5C; Fig. S6B), with a 
significant, rapid reduction in mCry1 when cells are infected at CT18 (Fig. 5C). This is 
consistent with MuHV-4 infection ushering cells from a repressive circadian phase to one 
where BMAL1 is active, via sustaining Bmal1 expression and relieving CRYPTOCHROME-
mediated repression. Furthermore, HSV-1 infection also acutely upregulated Bmal1 (Fig. 
5D), even more so than MuHV-4, suggesting that Bmal1 is specifically targeted by both α- 
and γ-herpesvirus families. In support of this, Bmal1 expression is induced in cells 
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overexpressing viral transcriptional activators from either herpesvirus (Fig. S7), and previous 
reports have demonstrated an interaction between BMAL1/CLOCK and several HSV-1 
transcriptional activators in vitro (22, 23). 
 
Influenza virus infection is augmented in arrhythmic cells 
Herpesviruses co-opt cellular transcriptional mechanisms in order to replicate and target 
clock transcription factors (Fig. 5). We next asked if the impact of BMAL1 ablation on viral 
infection extended beyond direct transcriptional regulation, to the global changes in cellular 
physiology that occur when circadian rhythms are disrupted. To investigate this, we infected 
WT and Bmal1–/–cells with the orthomyxovirus, influenza A (IAV) (Fig. 6A and B). IAV 
replicates within the nucleus but encodes its own RNA-dependent RNA polymerase and 
therefore does not directly employ the host cell’s transcriptional machinery for viral gene 
expression, in contrast to herpesviruses. Remarkably, loss of BMAL1 also significantly 
augmented IAV protein expression and replication (PB2::GLUC bioluminescence two-way 
ANOVA: genotype effect, P = 0.0004; single-cycle growth two-way ANOVA: genotype 
effect, P = 0.0102). The similar impact of cellular arrhythmicity on two disparate, clinically 
relevant virus families thus intimates a broader influence of circadian clocks, and specific 
components such as BMAL1, on viral infection. 
 
Pathways linking the clock and virus infection 
To determine which cellular systems underpin the time-of-day effect on viral replication, we 
first identified proteins that exhibit a change in abundance between two opposite circadian 
phases (CT18 vs. CT30) in WT cells. At these times, viral replication in WT, but not in 
Bmal1–/– cells, is significantly different (see Fig. 4C). Given that virus infection is augmented 
in Bmal1–/– cells at both time points (see Fig. 4C), we then focused on the subset of proteins 
within this group whose abundance was either increased or decreased at both these times in 
Bmal1–/– cells compared with WT cells (Fig. 6C and D; see also Fig. S8). Circadian-
regulated proteins expressed at higher levels in Bmal1–/– cells are enriched for those involved 
in protein biosynthesis (Figure 6C; see also Figure S8A and Table S1), including amino acid 
biosynthesis, ribosome structure, translation and protein folding clusters. Additionally, 
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proteins involved in endoplasmic reticulum function, protein localization and intracellular 
vesicle trafficking are significantly enriched. This indicates that enhanced capability for viral 
protein biosynthesis, assembly and egress contribute to clock control of virus replication.   
Conversely, circadian-regulated proteins expressed at lower levels in Bmal1–/– cells 
are enriched for those involved in organization of the cortical actin cytoskeleton and 
chromatin assembly (Fig. 6D; see also Figure S8B and Table S2), suggesting that virus 
particle uncoating, genome trafficking and histone association contribute to clock control of 
virus replication. Thus, the clock-mediated effects on viral infection in cells can be ascribed 
to discrete functional categories of protein effectors targeting specific aspects of the virus 
replication cycle.  
 
Discussion 
Our results show that altering only the time at which the host is infected can significantly 
alter the extent of virus infection and dissemination in vivo, reflecting the profound change in 
physiology that naturally occurs over the course of a day. Host circadian rhythms underpin 
this phenomenon, since behaviorally arrhythmic mice do not exhibit time-dependent 
differences in virus infection. Indeed, the degree to which these intracellular pathogens 
replicate is a function of circadian time in isolated cells, without systemic circadian cues or 
host defenses.  
For pathogens such as Plasmodia, which cause malaria, synchronizing their 
replication cycle with the host circadian rhythm contributes to their success (24). Likewise, 
we speculate that co-evolution of viruses with their hosts may have enabled them to capitalize 
on the predictability of daily rhythms driven by cell-autonomous molecular clocks. 
Comparable to our findings with herpesviruses, rhythmic gene expression can persist during 
hepatitis C virus and influenza A virus infection, albeit with altered circadian phase and 
amplitude (25, 26). Whether such changes to host circadian rhythms enhance virus 
propagation between cells or transmission between hosts are open questions.  
A key feature of cellular clocks is their ability to entrain to external stimuli; initial 
time-of-day effects would amplify if dysregulated timekeeping cues perpetuate from infected 
to neighboring uninfected cells. Our results strongly suggest that herpesvirus and IAV 
replication increases in arrhythmic cells, as demonstrated by virus-induced disruption at 
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certain circadian times or via loss of BMAL1. However, does this help or hinder persistence 
at the level of the host or population? HSV-1 disseminates more extensively in Bmal1-/- mice, 
for example, but augmented primary productive replication may generate more robust 
adaptive immune responses.  
How do viruses engage with the molecular clockwork and modulate timekeeping? At 
the simplest level, the circadian activity of host metabolic and trafficking pathways places 
constraints on replication. In turn, many viruses reprogram cellular metabolism, which can 
directly feed back to the core clock mechanism. A more intriguing possibility is that viruses 
can actively gauge the cellular circadian phase via interaction with core clock components, 
and exploit subsequent circadian variation in replication kinetics. The HSV-1 viral 
transactivator ICP0 is thought to directly associate with BMAL1, while viral transcription is 
driven by a complex containing CLOCK (22, 23, 27).  But why not associate with CLOCK 
directly, and why use BMAL/CLOCK at all? The abundance of CLOCK does not oscillate, 
and its circadian function is bestowed via interaction with BMAL1. We propose that 
herpesviruses recruit BMAL/CLOCK to tie viral transcription and cellular circadian time.  
We found that ICP0 induces Bmal1 expression outside the context of infection. This 
implies that Bmal1 is specifically targeted, rather than a cell-intrinsic innate immune response 
to infection. However, this presents an apparent paradox, given that replication is enhanced in 
the absence of BMAL1. Why induce a protein that appears to exert an anti-viral effect? 
Shifting cells from a repressive circadian phase via concomitant acute induction of Bmal1 
and repression mCry1 will likely stimulate replication. One straightforward explanation is 
therefore that chronic arrhythmicity in Bmal1-/- cells generates a cellular environment less 
equipped to deal with viral challenge, or that baseline levels of BMAL1 contribute to cell 
intrinsic anti-viral immune responses (e.g. via interferon signaling). Examining viral 
pathogenicity in alternate ‘clock knockout’ genetic models, and in hosts subject to chronic 
circadian desynchrony, will help disentangle such possibilities. This result additionally 
highlights the complex nature of circadian investigations, in that clock proteins may be co-
opted during virus replication in ways unrelated to their timekeeping function (“non-
circadian” effects). The global effect of circadian rhythms must be considered, rather than 
just the effect of individual clock components.  
 Our work does imply that constitutively low levels of BMAL1 can lead to increased 
herpes and influenza A viral infection. Remarkably, as well as its daily oscillation, Bmal1 
expression undergoes seasonal variation in human blood samples, with lowest levels during 
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the winter months (28). We speculate that this could contribute to viral dissemination at the 
population level since many viruses, including influenza, cause infection more commonly in 
the winter (29). Interestingly, Bmal1 controls circadian rhythms in immune cell trafficking 
and pathogen recognition by induction of Toll-like Receptor 9 (TLR9), highlighting its 
additional role in adaptive immunity at the whole organism level (30-32). Given that global 
Bmal1 expression in macrophages and natural killer cells is substantially lower in mouse 
models of shift work (chronic jet lag) (33-35), our work suggests that shift workers might be 
more susceptible to viral disease and would therefore be prime candidates for vaccination 
against viruses such as influenza. Indeed, timing of influenza vaccine administration in the 
morning vs. afternoon has recently been shown to be a determinant in systemic immunization 
response in people aged >65 years (36). Beyond this, acute manipulation of the molecular 
circadian clockwork may provide a strategy for the development of novel anti-viral therapies. 
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Methods 
 
Mice: All animal experimentation was licensed by the Home Office under the Animals 
(Scientific Procedures) Act 1986, with Local Ethical Review by the University of Cambridge. 
Animals had ad libitum access to regular chow and water, and were maintained at 22oC on a 
standard 12 h light:12 h dark cycle. Zeitgeber Time (ZT) is defined such that ZT0 is the time 
of “lights on”, and ZT12 as “lights off” in a standard 12 h light:12 h dark cycle. At the stated 
ZT, age-matched (6-12 week old) female littermate wild type (WT; Bmal1+/+) and Bmal1-/- 
mice on the C57Bl/6J genetic background were infected intranasally with 1x104 plaque 
forming units (p.f.u.) M3:luc MuHV-4 or 5x106 p.f.u. CMV:luc HSV-1 by scarification of the 
left ear. Bioluminescence imaging was performed with an IVIS Lumina and signal intensity 
quantified using Living Image software (Caliper Life Sciences). See SI Methods for further 
details.  
 
Cell culture and bioluminescence assays: Primary fibroblasts were generated as described 
previously (37). All cells were propagated in supplemented Dulbecco’s modified Eagle 
medium (DMEM) containing 4.5 g/l glucose (Sigma D6546), 10% (v/v) FetalClone III serum 
(Thermo Scientific HyClone), 1X Glutamax (Life Technologies), 100 U penicillin/ml and 
100 µg/ml streptomycin (Penicillin–Streptomycin Solution, Sigma P0781). For monitoring of 
circadian transcriptional rhythms, NIH3T3 fibroblasts (ATCC) were transiently transfected 
with mPeriod2:luciferase (Per2:luc), mCryptochrome1:luciferase (Cry1:luc) or 
Bmal1:luciferase (Bmal1:luc) reporter constructs (38). For real-time bioluminescence 
recordings, confluent cells were temporally synchronized by temperature cycles (32oC:37oC; 
12 h:12 h), treatment with 100 nM dexamethasone or serum shock, transferred to “Air 
Medium” and bioluminescence analyzed using a LumiCycle-32 system (Actimetrics) (39). 
For comparison between different experiments, and with in vivo work, peak Bmal1:luc 
bioluminescence was operationally designated as Circadian Time (CT) =  0/24h. See SI 
Methods for further details.  
 
Viruses: Wild type (WT) MuHV-4 (MHV-68), M50 MuHV-4 (40), M3:luciferase (M3:luc) 
MuHV-4 (15), WT HSV-1 (SC16 strain) and CMV:luciferase (CMV:luc) HSV-1 (18) stocks 
were grown in BHK21 cells. Virus titre was determined by plaque assay based on the 
methodology of Russell (41). PB2::Gaussia luciferase (PB2::GLUC) influenza A virus 
[mouse-adapted strain A/Puerto Rico/8/34 H1N1 (PR8-Gluc)] was a kind gift from Nicholas 
Heaton and Peter Palese (Icahn School of Medicine at Mount Sinai, New York, USA)(42). 
WT and PB2::GLUC stocks were amplified (48 h at 37oC) in 10-day old embryonated 
chicken eggs and stocks titrated by plaque assay. See SI methods for further details 
 
Bioluminescence virus infection assays in cells: For investigation of single-cycle MuHV-4 
replication in vitro, adherent cells were cultured to confluence, transferred to “Air Medium” 
(see SI methods) and infected with M3:luc MuHV-4 or CMV:luc HSV-1 at high multiplicity 
of infection (MOI = 1-3 p.f.u./cell). Bioluminescence was monitored in real-time using a 
Lumicycle-32 (Actimetrics), as above, or with a custom Alligator Bioluminescence Incubator 
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System (Cairn Research, UK). To assess single-cycle influenza A virus (IAV) replication in 
vitro, confluent adherent cells were infected with PB2::GLUC IAV (MOI = 2 pfu/cell). 
Gaussia luciferase is naturally excreted from cells and >60% of total luciferase produced 
during infection is extracellular (42). Cell culture medium was sampled at the stated times 
post-infection and luciferase activity subsequently determined using a BioLux Gaussia 
luciferase Assay Kit (NEB E3300L) according to manufacturer’s instructions.  
 
Proteomics: Synchronized, confluent primary WT and Bmal1-/- fibroblasts were harvested at 
either CT = 18h or CT = 30h. Lysates were pre-cleared, reduced with TCEP and alkylated 
with iodoacetamide. After quenching alkylation with acetone, protein samples were digested 
with trypsin and labeled with tandem mass tags (TMT) according to the manufacturer’s 
instructions (Thermo). Peptides were dried by vacuum centrifugation and cleaned for LC-
MS/MS analysis using C18 Stage Tips with a centrifuge-based protocol. Peptide mixtures 
were separated on a 50 cm, 75um I.D. Pepmap column over a 3 h gradient at 40°C and eluted 
directly into the mass spectrometer (Thermo Q Exactive Orbitrap). Xcalibur software was 
used to control the data acquisition. MaxQuant v1.5.2.8 was used to process the raw data 
acquired with a reporter ion quantification method. The Uniprot KB database of mouse 
sequences was used for peptide identification. A peptide estimated false discovery rate (FDR) 
of 0.1% was used to generate tables with protein and peptide identifications and 
quantifications. Two-tailed t-tests were performed in Perseus using a false discovery rate 
(FDR) cut-off of 0.05 and a within groups variance S0 factor of 0.1 (43). Proteins showing 
significant difference between CT18 and CT30 in WT cells, but not Bmal1-/- cells, were 
subsequently tested via two-tailed t-test for significant differences between WT and Bmal1-/- 
cells at both CT18 and CT30 (FDR cut-off 0.05) and presented graphically in R using the 
HeatMap package (See Fig. S6C and D). Proteins meeting both significance criteria were 
then subject to DAVID Functional Annotation Clustering analysis (See Table S1 and Table 
S2). Outputs were graphically presented using Cytoscape EnrichmentMap application and 
annotated using Clustermaker Markov Cluster Algorithm and WordCloud (44, 45). See SI 
Methods for further details.  
 
Statistical analysis: Unless otherwise stated, statistical analysis was performed using Prism 
(GraphPad Software). “n” refers to number of biological replicates throughout. For circadian 
luciferase reporters, moving-average baseline-subtracted (detrended) bioluminescence values 
were calculated using LumiCycle Data Analysis software (Actimetrics). See SI Methods for 
further details.  
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Figure legends 
  
Fig. 1. Herpesvirus infection in mice is regulated by the circadian clock.  
 
(A) Wild type (WT) female mice were infected with M3:luciferase Murid Herpesvirus 4 
(M3:luc MuHV-4) at either Zeitgeber Time 0 (ZT0) (“lights on”; n=6) or at ZT10 (n=6). The 
schematic illustrates the anticipated levels of Bmal1 mRNA and active (genome-bound) 
BMAL1 protein over the day and night. Extent of infection was monitored by 
bioluminescence imaging on the days shown. Primary infection in the nose is higher when 
infection occurs at the onset of the resting period (ZT0) compared with infection just before 
to the active period (ZT10) (mean±SEM; two-way ANOVA (time of initial infection x time 
post-infection): time of initial infection effect P=0.0021; post-hoc t-tests *P<0.05). See also 
Fig. S1A.  
(B) Female Bmal1-/- mice were infected with M3:luc MuHV-4 at either ZT0 (n=5) or ZT10 
(n=6) and extent of infection was monitored as above (mean±SEM; two-way ANOVA (time 
of initial infection x time post-infection): time of initial infection effect P>0.05; NS = not 
significant). See also Fig. S1B.  
  
18 
 
Fig. 2. Herpesvirus infection is augmented in arrhythmic Bmal-/- mice.  
 
(A) WT (n=6) and Bmal1-/- (n=5) female mice were intranasally infected with M3:luc MuHV-
4 at ZT7. Extent and spread of infection was monitored by bioluminescence imaging on the 
stated days. Representative images (of at least n=5 biological replicates per group) are shown 
with overlaid bioluminescence radiance measurements.  
(B) M3:luc MuHV-4 progressively disseminates from the nose to the superficial cervical 
lymph nodes (SCLN) and is significantly higher in Bmal1-/- mice (mean±SEM; Nose two-
way ANOVA (genotype x time post-infection): genotype effect *P=0.0031; Superficial 
cervical lymph nodes (SCLN) two-way ANOVA (genotype x time post-infection): genotype 
effect P=0.0348; post-hoc t-tests *P<0.05, **P<0.01, ***P<0.001). For individual data 
points see Fig. S2A. 
(C) Male WT (n=5) and Bmal1-/- (n=6) mice were infected with CMV:luciferase (CMV:luc) 
herpes simplex virus 1 (HSV-1) by scarification of the left ear at ZT7. Extent and spread of 
infection was monitored by bioluminescence imaging on stated days, as in (A).  
(D) CMV:luc HSV-1 progressively disseminates from the left ear to the head and right ear, 
and is increased significantly in Bmal1-/- mice (mean±SEM; left ear two-way ANOVA 
(genotype x time post-infection): genotype effect P=0.0004; right ear two-way ANOVA 
(genotype x time post-infection): genotype effect P=0.0054; post-hoc t-tests *P<0.05, 
**P<0.01). For individual data points see Fig. S2E. 
  
19 
 
Fig. 3. Circadian rhythms modulate herpesvirus replication in cells.  
 
(A) Bioluminescence traces from control (uninfected) temperature-synchronized 
Bmal1:luciferase (Bmal1:luc) and Per2:luciferase (Per2:luc) circadian reporter NIH3T3 cells 
(mean±SEM; n=3). Peak Bmal1:luc bioluminescence is designated Circadian Time 24 
(CT24). Colored arrows indicate circadian times (CT) at which parallel cultures of 
temperature-synchronized NIH3T3 cells were infected with M3:luc MuHV-4.  
(B) Schematic showing a respresentative bioluminescence recording and kinetic analysis of 
M3:luc MuHV-4 replication parameters using asymmetrical sigmoidal non-linear regression. 
See Fig. S4A and B for raw bioluminescence recordings obtained from cells infected at 
different CTs and R2 regression coefficients.  
(C) Amount of MuHV-4 replication varies significantly depending on the circadian time of 
infection (mean±SEM; n=3; one-way ANOVA: total bioluminescence P=0.0178; multiple 
comparisons *P<0.05). Total bioluminescence calculated by the area under curve method 
(AUC) and normalized (0% = baseline total bioluminescence between 0 – 1h post-infection, 
100% = maximum total bioluminescence values). The variation in total bioluminescence 
across different CTs is presented (% total bioluminescence – mean % total bioluminescence 
values for all experimental CTs). See Fig. S4C for Pearson’s correlation analysis of total 
bioluminescence and infectious particle production (Log10 [plaque-forming units]). Open 
arrowheads highlight CT18/24 (high infection) and solid arrowheads highlight CT30/36 (low 
infection).  
(D) The rate of viral gene expression varies significantly depending on the circadian time of 
infection (one-way ANOVA: Hill Slope P<0.0001; post-hoc multiple comparisons: 
**P<0.01, ***P<0.001).  
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Fig. 4. Herpesvirus replication is enhanced in Bmal1-/- cells.  
 
(A) Pseudo-colored bioluminescence image of wild type (WT) and Bmal1-/- primary cells 
infected with M3:luc MuHV-4. See also Movie S2.  
(B) Representative bioluminescence recordings showing synchronized WT and Bmal1-/- 
primary cells infected with M3:luc MuHV-4 (mean±SEM; n=3).  
(C) Synchronized WT and Bmal1-/- primary cells were infected with M3:luc MuHV-4 at 
either CT18 or CT30. MuHV-4 replication is significantly increased in Bmal1-/- cells 
compared with WT cells (mean±SEM; n=3)(Total bioluminescence (AUC) normalized as for 
Fig. 3C; two-way ANOVA (genotype x circadian time of infection): genotype effect 
P<0.0001). Time-of-day effect on viral replication is observed in WT cells, but not Bmal1-/- 
cells (Total bioluminescence two-way ANOVA (genotype x circadian time of infection): 
post-hoc multiple comparisons: NS=not significant, *P<0.05). See Fig. S4C for correlation 
analysis of total bioluminescence and infectious particle production (Log10 [p.f.u.]) and Fig. 
S5 for circadian reporter controls and M3:luc MuHV-4 kinetic analysis.  
(D) Pseudo-colored bioluminescence image of wild type (WT) and Bmal1-/- primary cells 
infected with CMV:luc HSV-1. See also Movie S3.  
(E) CMV:luc HSV-1 replication is increased significantly in Bmal1-/- cells compared to WT 
cells (mean±SEM; n=3). Total bioluminescence (AUC) normalized as for Fig. 3C (two-tailed 
t-test: ***P<0.001). See Fig. S4E for correlation analysis of total bioluminescence and 
infectious particle production (Log10 [p.f.u.]). 
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Fig. 5. Virus infection differentially affects clock gene expression.  
 
(A) Bioluminescence recordings from synchronized Bmal1:luciferase (Bmal1:luc) circadian 
reporter NIH3T3 cells either mock infected or infected with MuHV-4 at CT18 (open 
arrowhead) and CT30 (solid arrowhead). Mean baseline-subtracted (detrended) 
bioluminescence (n=3 per group) shown. Infection at CT18 generates an additional peak in 
Bmal1:luc expression, disrupting the circadian rhythm, whereas increased Bmal1:luc 
expression after infection at CT30 synergizes with circadian Bmal1:luc expression and 
rhythms are preserved during infection.  
(B) Peak bioluminescence from synchronized Bmal1:luc cells either mock-infected or 
infected with MuHV-4 at 3 h intervals from CT18 to CT39 (mean±SEM; n=3). Bmal1:luc 
expression is significantly increased, irrespective of the circadian time of infection (one-way 
ANOVA P<0.0001; post-hoc multiple comparisons: *P<0.05, **P<0.01, ***P<0.001). For 
raw bioluminescence recordings and error boundaries see Fig. S6.  
(C) Bioluminescence traces from synchronized mCryptochrome1:luciferase (Cry1:luc) 
circadian reporter NIH3T3 cells (mean; n=3). Insert panel shows raw bioluminescence traces 
(mean±SEM; n=3). Cry1:luc is significantly decreased during MuHV-4 infection (post-
infection peak bioluminescence two-tailed t-test *P=0.0188).  
(D) Bioluminescence recording from synchronized Bmal1:luc cells mock-infected or infected 
with HSV-1 at CT36 (solid arrowhead)(mean±s.e.m; n=3). Bmal1:luc expression is 
significantly increased during HSV-1 infection (post-infection peak bioluminescence two-
tailed t-test ***P<0.001). 
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Fig. 6. Global proteomic comparison of wild type (WT) and Bmal1-/- cells reveals clock-
regulated pathways that impact on viral replication.  
 
(A) Influenza A viral protein expression is enhanced in Bmal1-/- cells. WT and Bmal1-/- cells 
were infected with PB2::GLUC (Gaussia luciferase) influenza A virus (IAV) and emitted 
photons quantified at stated intervals. PB2 is expressed with more rapid kinetics in Bmal1-/- 
compared to WT cells (mean±SEM; n=3; two-way ANOVA (genotype x time post-
infection): genotype effect P=0.0004, interaction P<0.0001; post-hoc multiple comparisons: 
*P<0.05, **P<0.01, ***P<0.001). Levels were also higher in Bmal1-/- cells (sigmoidal non-
linear regression: WT R2 = 0.9902, Bmal-/- R2 = 0.9836; plateau PB2::GLUC 
bioluminescence two-tailed t-test: ***P<0.001; F-test P<0.001; Total PB2::GLUC 
bioluminescence (AUC) two-tailed Student’s t-test: **P<0.0019).  
(B) Single-cycle IAV growth is enhanced in Bmal1-/- cells. At the stated times, IAV-infected 
cells were harvested and the amount of infectious IAV particles determined by plaque assay. 
Results shown are representative of two independent experiments. Production of virus 
particles is significantly enhanced in Bmal1-/- cells (two-way ANOVA (genotype x time post-
infection): genotype effect *P=0.0102). 
(C) Synchronized WT and Bmal1-/- primary cells were harvested at CT18 and CT30 and 
global proteomics performed by liquid chromatography coupled to mass spectrometry. 
Database for Annotation, Visualization and Integrated Discovery (DAVID) Functional 
Annotation Clustering analysis was performed on candidate proteins whose abundance 
significantly changes at CT18 vs. CT30, and is significantly increased in Bmal1-/- cells 
compared to WT cells at both CT18 and CT30. Number of proteins is represented by node 
size and cluster P-value by node greyscale. Annotations were prescribed by a Markov Cluster 
Algorithm and text size represents number of nodes per group. A heat map (left) is shown for 
n=3 biological replicates per genotype and time-point (see also Fig. S8A). Enrichment scores 
are shown in Table S1.  
(D) Proteomics analysis performed as in (A). DAVID Functional Annotation Clustering 
analysis of candidate proteins whose abundance significantly changes at CT18 vs. CT30, and 
is significantly decreased in Bmal1-/- cells compared to WT cells at both CT18 and CT30. 
Proteins are represented as in (A). A heat map (left) is shown for n=3 biological replicates per 
genotype and time point (see also Fig. S8B). Enrichment scores are shown in Table S2.   
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SI Figure legends 
 
Fig. S1. M3:luc MuHV-4 infection in wild type (WT) and Bmal1-/- mice infected 
at ZT0 versus ZT10.  
 
(A) Individual subject plots from Fig. 1A. WT mice show higher levels of MuHV-4 
infection at ZT0 vs. ZT10 (mean±SEM; n=6).  
(B) Individual subject plots from Fig. 1B. No significant difference in MuHV-4 
pathogenesis is observed in Bmal1-/- mice infected at ZT0 (n=5) and ZT10 (n=6) 
(mean±s.e.m).  
(C) No significant difference in MuHV-4 intranasal infection is observed between 
WT and Bmal1-/- mice infected at ZT0 (mean±SEM; n=5 (Bmal1-/- group), n=6 (WT 
group)); maximum radiance two-way ANOVA (genotype x time post-infection): 
genotype effect P>0.05; NS=not significant).  
(D) MuHV-4 intranasal infection is significantly greater in Bmal1-/- mice versus WT 
mice infected at ZT10 (mean±SEM; n=6; maximum radiance two-way ANOVA 
(genotype x Time post-infection): genotype effect ***P<0.001; post-hoc t-test 
**P<0.01 ***P<0.001).  
(E) No significant difference in MuHV-4 infection of the superficial cervical lymph 
nodes (SCLN) is observed between WT mice infected at ZT0 vs. ZT10, or between 
Bmal1-/- mice infected at ZT0 vs. ZT10   (maximum radiance two-way ANOVA (time 
of infection x time post-infection): time of infection effect P>0.05, NS=not 
significant).  
(F) MuHV-4 SCLN infection in WT and Bmal1-/- mice infected at ZT0 and ZT10. 
SCLN infection is significantly higher in Bmal1-/- mice vs. WT infected at ZT10 on 
day 9 post-infection (post-hoc t-test *P<0.05). 
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Fig. S2. M3:luc MuHV-4 and CMV:luc HSV-1 primary and latent infection in 
wild type (WT) and Bmal1-/- mice.  
 
(A) Individual subject plots from Fig. 2B. During primary infection, MuHV-4 
progressively spreads from the nose to SCLN (mean±SEM; n=5 (Bmal1-/- group), n=6 
(WT group)). Infection in the nose and SCLN is significantly higher in Bmal1-/- mice 
vs. WT  (nose maximum radiance two-way ANOVA (genotype x time post-
infection): genotype effect P=0.0031; SCLN maximum radiance two-way ANOVA 
(genotype x time post-infection): genotype effect P=0.0348).  
(B) 24 days after infection, mice were culled. Latent viral genome loads in the spleen 
were analysed by quantitative real-time PCR (qPCR), which compares MuHV-4 M2 
gene copy number with cellular APRT gene copy number (1000xM2/APRT) 
(mean±SEM; n=5 (Bmal1-/- group), n=6 (WT group); two-tailed t-test P>0.05; F-test 
***P=0.0001). See Methods for further details.  
(C) Reactivation of latent MuHV-4 in the spleen was assessed by the number 
infectious centres (plaques) on cell monolayers co-cultured with ex vivo splenocytes 
(mean±SEM; n=5 (Bmal1-/- group), n=6 (WT group); two-tailed t-test P>0.05; F-test 
*P=0.0228). Thus, no statistically significant difference between mean values of 
MuHV-4 latent infection was observed by either infectivity assay.  
(D) Dissemination of HSV-1 infection from the left ear to the chest is significantly 
increased in Bmal1-/- mice vs. WT (chest maximum radiance two-way ANOVA 
(genotype x time post-infection): genotype effect P=0.0037).  
(E) Individual subject plots from Fig. 2D. During primary infection, HSV-1 
progressively spreads from the left ear to the right ear and chest (mean±SEM; n=5 
(WT group); n=6 (Bmal1-/- group)). Infection in the left ear is significantly higher in 
Bmal1-/- mice vs. WT (maximum radiance two-way ANOVA (genotype x time post-
infection): genotype effect P=0.0004). HSV-1 spreads to secondary sites more 
effectively in Bmal1-/- mice vs. WT: n=4 of 6 Bmal1-/- mice showed substantial 
infection in the right ear, whereas this is evident in only n=1 of 5 WT mice. Similarly, 
n=5 of 6 Bmal1-/- mice showed dissemination of HSV-1 to the chest, versus n=3 of 5 
WT mice. Virus infection in the chest is significantly increased in Bmal1-/- mice 
compared to WT (maximum radiance two-way ANOVA (genotype x time post-
infection): genotype effect P=0.0037).  
(F) 24 days after infection, mice were culled. Viral genome loads in the dorsal root 
ganglion were analysed by quantitative real-time PCR (qPCR), which compares HSV-
1 ICP0 gene copy number with cellular APRT gene copy number (1000xICP0/APRT). 
See Methods for further details. No statistically significant difference in HSV-1 latent 
genome load was observed (two-tailed t-test P>0.05). 
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Fig. S3. Replicative activity of confluent cell monolayers post-synchronization. 
 
(A) Confluent NIH-3T3 cell monolayers stably transduced with dual FUCCI reporters 
amCyan::Geminin and mCherry::Cdt1 were trypsinized, stained with DNA dye 
DRAQ5 and analyzed by flow cytometry. mCherry::Cdt1 is expressed during G1 
phase (2n DNA content), whereas amCyan::Geminin is expressed during S/G2 phase 
(2<n≤4 DNA content). 
 
(B) Representative images of confluent FUCCI reporter NIH-3T3 cell monolayers at 
different circadian times post-synchronization (red indicates mCherry::Cdt1; blue 
indicates amCyan::Geminin; see also Movie S1).  
 
(C) Confluent FUCCI reporter NIH-3T3, primary WT and Bmal1-/- fibroblast 
monolayers were synchronized and imaged between circadian time (CT) 0 – 66h (see 
also Movie S1). Cells expressing either amCyan::Geminin or mCherry::Cdt1 were 
counted at the stated CTs (n = 5 fields of view for each cell type; > 300 cells observed 
per time point). Across all CTs, G2 phase amCyan::Geminin-positive cells accounted 
for 5.60±1.4%, 1.70±0.31% and 3.35±0.79% (mean±SEM) of 3T3s, WT and  Bmal1-/- 
monolayers, respectively. Linear regression analysis shows a significant negative 
correlation between time post-synchronisation and % G2 phase amCyan::Geminin-
positive cells for NIH-3T3 and Bmal1-/- fibroblasts, but not for WT fibroblasts (3T3s: 
R2 = 0.9223, Pearson r = -0.960, P<0.001; Bmal1-/-: R2 = 0.965, Pearson r = -0.9780, 
P<0.001; WT: R2 = 0.317, Pearson r = -0.563, P=0.1145). Critically, for all three cell 
types we could detect no circadian oscillation in the ratio of G1 to G2 phase cells. 
Damped sine wave modeling (non-linear regression) yields best-fit period values > 
50h (not within circadian range 18 – 30h) and 2-way ANOVA (cell cycle phase x 
circadian time): circadian time effect P > 0.05. Additionally, comparison of cell cycle 
phase markers between WT and Bmal1-/- cell types at each circadian time by multiple 
two-tailed t-tests revealed no significant results (false discovery rate (FDR) Q = 1%).  
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Fig. S4. Kinetics and total amount of MuHV-4 single-cycle replication are a 
function of the circadian time at which cells are infected.  
 
(A) Raw bioluminescence recordings from temperature-synchronized NIH3T3 cells 
infected with M3:luc MuHV-4 at 6h intervals from CT42-CT66 (mean; n=3). cps = 
counts per second.  
(B) Coefficients of determination (R2) for asymmetric sigmoidal non-linear regression 
of data from Fig. 3.  
(C) Parallel cultures of primary WT fibroblasts were incubated with M3:luc MuHV-4 
at different multiplicities of infection (MOI) between 0.001 - 2 plaque-forming units 
(p.f.u.) per cell. After 2h, cells were acid-washed to remove the input virus. Real-time 
bioluminescence was recorded and the amount of infectious MuHV-4 particles 
produced at 0, 12, 24, 48 and 96h post-infection was determined by plaque assay 
(mean±SEM; n=3). Over this range of MOI, total bioluminescence during exponential 
growth (area under curve, AUC) linearly correlates with Log10 (p.f.u) (linear 
regression analysis: R2 = 0.677, P<0.0001; Pearson’s r = 0.823; a 23.56% difference 
in total bioluminescence ≈ 10-fold change p.f.u.).  
 
(D) Time to 50% peak infection and 50% decrease in peak infection varies 
significantly depending on the circadian time of infection (mean±SEM; n=3; one-way 
ANOVA: time to 50% peak infection P=0.0002; one-way ANOVA: time to 50% 
decrease in peak infection, P<0.0001; post-hoc multiple comparisons: **P<0.01 
***P<0.001). Over each circadian cycle, there is a significant linear correlation 
between the time to 50% peak infection and the time to 50% decrease in peak 
infection (Pearson’s r=0.999 (1st cycle) P=0.022; or r=0.982 (2nd cycle) P=0.006). 
Infection is sustained less robustly at circadian times that yield more rapid viral gene 
expression initially, with the entire kinetic profile of infection depending on the 
circadian time of infection.   
 
(E) Parallel cultures of NIH-3T3 fibroblasts were incubated with CMV:luc HSV-1 at 
different multiplicities of infection (MOI) between 0.001 - 10 p.f.u. per cell. After 1h, 
cells were acid-washed to remove the input virus. Real-time bioluminescence was 
recorded and the amount of infectious MuHV-4 particles produced at 0, 8, 24, 48 and 
72h post-infection was determined by plaque assay (mean±SEM; n=3). Over this 
range of MOI, total bioluminescence during exponential growth (AUC) linearly 
correlates with Log10 (p.f.u) (linear regression analysis: R2 = 0.706, P = 0.0002; 
Pearson’s r = 0.840; 15.9% difference in total bioluminescence ≈ 10-fold change 
p.f.u.).  
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Fig. S5. Circadian time effect on MuHV-4 kinetics in WT but not Bmal1-/- cells. 
 
(A) Dexamethasone-synchronized mPeriod2:luciferase (Per2:luc) and Bmal1: 
luciferase (Bmal1:luc) circadian reporter fibroblasts (mean±SEM; n=3). Circadian 
controls for synchronization protocol used in Fig. 4C, Fig. 6C and D. In Fig. 4C, 
dexamethasone-synchronized WT and Bmal1-/- primary cells were infected with 
M3:luc MuHV-4 at either CT18 (open arrowhead) or CT30 (solid arrowhead).  
 
(B) Kinetic analysis of experiment described in Fig. 4C. Kinetic analysis was 
performed as shown in Fig. 3B (R2 regression coefficients: WT CT18 = 0.9782, WT 
CT30 = 0.9932, Bmal1-/- CT18 = 0.9668, Bmal1-/- CT30 = 0.9768). Time to 50% peak 
infection is significantly decreased in Bmal1-/- cells compared with WT cells (two-
way ANOVA (genotype x circadian time of infection): genotype effect P<0.0001). 
Time-of-day effect on viral replication is observed in WT cells, but not Bmal1-/- cells 
(time to 50% peak infection two-way ANOVA (genotype x circadian time of 
infection): post-hoc multiple comparisons: NS=not significant, ***P<0.001).  
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Fig. S6. MuHV-4 infection rapidly induces Bmal1 expression.  
 
(A) Raw and detrended (baseline-subtracted) bioluminescence recordings from 
synchronized Bmal1:luc circadian reporter NIH3T3 cells either mock-infected or 
infected with MuHV-4 at 3 h intervals from CT=18h to CT=39h (CT=circadian time). 
Grey lines indicate CT of infection. Top panel: raw Bmal1:luc bioluminescence 
recordings (counts per second, cps) (mean±SEM boundaries; n=3). Bottom panel: 
detrended Bmal1:luc bioluminescence analysis (moving-average subtracted; 
mean±SEM boundaries; n=3). Selected data are presented in Fig. 5A (infection at 
CT=18 and 30h) and peak Bmal1:luc bioluminescence data are summarized in Fig 
5B.  
 
(B) Bioluminescence traces from synchronized Per2:luc circadian reporter NIH3T3 
cells (mean; n=3) either mock-infected or infected with MuHV-4 (grey line indicates 
CT of infection). Insert panel shows raw bioluminescence traces (mean±SEM).   
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Fig. S7. Bmal1 expression is induced in cells overexpressing herpesvirus 
transcriptional activators.  
 
(A) Synchronized NIH3T3 cells expressing Bmal1:luc transcriptional reporter were 
either mock-infected or infected with wild type (WT) MuHV-4 or M50 MHV-68, a 
recombinant virus that overexpresses ORF50, which encodes the main viral 
transcriptional transactivator. Bmal1:luc bioluminescence is significantly increased 
during M50 MuHV-4 infection, compared with WT MuHV-4 or mock infected 
controls (mean±SEM; n=3; one-way ANOVA: P=0.0049; post-hoc multiple 
comparisons: *P<0.05, **P< 0.01).  
(B) An adenoviral Tet-On system was used to investigate whether the HSV-1 viral 
transactivator Infected Cell Polypeptide 0 (ICP0) can initiate Bmal1 transcription. 
Synchronized NIH3T3 cells expressing the Bmal1:luc transcriptional reporter were 
infected with adenoviral constructs expressing rtTA from the HCMV IE promoter 
(Ad.CMV.rtTA), ICP0 under the control of a Tetracycline-Responsive (TRE) 
promoter (Ad.TRE.ICP0), a non-functional RING-finger deletion mutant (FXE) of 
ICP0 under the control of a TRE promoter (Ad.TRE.FXE), or a combination thereof. 
Doxycycline (Dox) was added 46 h after infection to enable transcription from the 
TRE promoter if rtTA is present. ICP0 significantly increases Bmal1:luc (% change 
3h pre-Dox vs. 3h post-Dox addition) compared to controls (mean±SEM; n=3; one-
way ANOVA: P=0.0038; post-hoc multiple comparisons: **P< 0.01, ***P< 0.001). 
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Fig. S8. Proteins that show significantly different expression levels at between 
WT and Bmal1-/- cells.  
 
(A) Proteins whose abundance significantly changes at CT18 vs. CT30, and is 
significantly increased in Bmal1-/- cells compared to WT cells at both CT18 and 
CT30. See Fig. 6C and Table S1 for Database for Annotation, Visualization and 
Integrated Discovery (DAVID) Functional Annotation Clustering analysis.  
(B) Proteins whose abundance significantly changes at CT18 vs. CT30, and is 
significantly decreased in Bmal1-/- cells compared to WT cells at both CT18h and 
CT30. See Fig. 6D and Table S2 for DAVID Functional Annotation Clustering 
analysis.  
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Table S1. Enrichment cluster scores and P-values of DAVID enrichment 
analysis. 
 
DAVID Functional Annotation Clustering analysis for candidate proteins whose 
abundance significantly changes at CT18 vs. CT30, and is significantly increased in 
Bmal1-/- cells compared to WT cells at both CT18 and CT30. Gene ontology terms 
with P<0.05 shown. See Fig. 6C for diagrammatic presentation of results.  
 
 
 
Table S2. Enrichment cluster scores and P-values of DAVID enrichment 
analysis.  
 
DAVID Functional Annotation Clustering analysis for proteins whose abundance 
significantly changes at CT18 vs. CT30, and is significantly decreased in Bmal1-/- 
cells compared to WT cells at both CT18 and CT30. Gene ontology terms with 
P<0.05 shown. See Fig. 6D for diagrammatic presentation of results. 
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Movie S1. FUCCI cell cycle reporter expression in confluent NIH-3T3 cells 
 
Confluent FUCCI mCherry::Cdt1(G1 phase)/amCyan::Geminin(S/G2 phase) reporter 
NIH-3T3 cell monolayers were synchronized and imaged between circadian time 
(CT) 0 – 66h. Cells expressing the G2 phase marker amCyan::Geminin (blue) account 
for < 20% of the total number and no circadian rhythm in mCherry::Cdt1/ 
amCyan::Geminin ratio is observed (see also Fig. S3). 
 
 
Movie S2. MuHV-4 replication is enhanced in Bmal1-/- cells 
 
Pseudo-colored bioluminescence recording of wild type (WT) and Bmal1-/- primary 
cells infected with M3:luc MuHV-4.  
 
 
Movie S3. HSV-1 replication is enhanced in Bmal1-/- cells. 
 
Pseudo-colored bioluminescence recording of wild type (WT) and Bmal1-/- primary 
cells infected with CMV:luc HSV-1. 
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SI Methods 
 
Mice 
Sample size was determined using the resource equation: E (degrees of freedom in 
ANOVA) =  (total number of experimental animals) – (number of experimental 
groups), with sample size adhering to the condition 10 < E < 20. For comparison of 
MuHV-4 and HSV-1 infection in WT versus Bmal1-/- mice at ZT7 (Fig. 2), 
investigator did not know the genotype of the animals when conducting infections, 
bioluminescence imaging and quantification. For bioluminescence imaging, mice 
were injected intraperitoneally with endotoxin-free luciferin (Promega E6552) using 2 
mg total per mouse. Following anaesthesia with isofluorane, they were scanned with 
an IVIS Lumina (Caliper Life Sciences), 15 min after luciferin administration. Signal 
intensity was quantified using Living Image software (Caliper Life Sciences), 
obtaining maximum radiance for designated regions of interest (photons per s per cm2 
per Steradian: photons s-1 cm-2 sr-1), relative to a negative control region. At 24 days 
post-infection, mice were culled and tissue removed for analysis of latent infection. 
 
Analysis of virus latency  
For analysis of MuHV-4 latent infection in mice, viral genome loads were measured 
by real-time PCR using DNA extracted from spleen tissue as previously described 
(15). MuHV-4 M2 gene were amplified using a Rotor Gene 3000 (Corbett Research) 
and PCR products quantified by hybridization with a Taqman probe. Genome copy 
number was determined by comparison to a standard curve of cloned M2 plasmid 
templates. Cellular DNA was quantified in parallel by amplifying part of the 
adenosine phosphoribosyl transferase gene (APRT) and the ratio of MuHV-4 genome 
copies to APRT determined. Reactivation of latent MuHV-4 was measured by 
infectious centre assay: Spleens were disrupted into single-cell suspensions and serial 
dilutions were co-cultured with cell monolayers. After 6 days, cells were fixed and 
stained for plaque counting, as above. For analysis of HSV-1 latent infection in mice, 
viral genome loads were measured by real-time PCR using DNA extracted from 
dorsal root ganglion tissue as previously described (46). HSV-1 ICP0 gene were 
amplified using a Rotor Gene 3000 and PCR products quantified by hybridization 
with a Taqman probe. Genome copy number was determined by comparison to a 
standard curve of cloned ICP0 plasmid templates. Cellular DNA was quantified in 
parallel by amplifying part of the APRT gene and the ratio of HSV-1 genome copies 
to APRT determined. 
 
Cell culture and bioluminescence assays 
All cells were propagated in Dulbecco’s modified Eagle medium (DMEM) containing 
4.5 g/l glucose (Sigma D6546) was supplemented with 10% (v/v) FetalClone III 
serum (Thermo Scientific HyClone), 1X Glutamax (Life Technologies), 100 U 
penicillin/ml and 100 µg/ml streptomycin (Penicillin–Streptomycin Solution, Sigma 
P0781). Transfections were conducted using GeneJuice transfection reagent 
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(Millipore). After synchronization, cells were transferred to “Air Medium”, 
containing [DMEM (Sigma D5030) supplemented with 5 g/l glucose, 20 mM HEPES, 
100 U penicillin/ml and 100 µg/ml streptomycin, 0.035% NaHCO3, FetalClone III 
serum, 1X Glutamax, 2X B-27® Supplement (Life Technologies 17504-044) and 0.3 
mM Luciferin (Biosynth L8220)]. All experiments were initiated > 24 h after cells 
were transferred to constant conditions, so that they would not be subject to any 
effects of the synchronization treatment. Bioluminescence was monitored using a 
LumiCycle-32 system (Actimetrics) and recordings were analysed using LumiCycle 
Data Analysis software (Actimetrics).  
 
 
Cell cycle analysis of confluent cell monolayers 
NIH-3T3, primary WT and Bmal1-/- fibroblasts were sequentially transduced with 
lentiviral fluorescent ubiquitin-based cell cycle indicators (FUCCI) mCherry::Cdt1 
and amCyan::Geminin reporters (47). Dual reporter-positive cells were selected by 
FACS (Influx Cell Sorter, BD Biosciences) and seeded into 35mm dishes for 
subsequent analysis. To confirm that expression of mCherry::Cdt1 and 
amCyan::Geminin correspond to G1 (2n DNA content) and S/G2 (2<n≤4 DNA 
content) cell cycle phases, respectively, cells were stained with DNA dye DRAQ5 
(abcam) and analysed by flow cytometry (LSR-Fortessa, BD Biosciences). To 
examine dynamics of replicative activity under experimental confluent conditions, 
synchronized FUCCI reporter monolayers were observed by time-lapse live cell 
imaging over 3 days (Nikon Eclipse Ti-E inverted epifluorescent microscope). At 
stated circadian times, numbers of mCherry::Cdt1- and amCyan::Geminin-positive 
cells were counted and their ratio determined.  
 
Viruses  
To generate MuHV-4 and HSV-1 stocks, infected BHK21 cells were harvested 
following the development of cytopathic effect. Virus titre was determined by plaque 
assay as follows. For MuHV-4, BHK21 or NIH 3T3 cell monolayers were incubated 
(2 h at 37oC) with 10-fold dilutions of virus then overlaid with 0.6% 
carboxymethylcellulose to limit progeny virus spread to adjacent cells only. After 4 
days, cells were fixed in 10% formaldehyde and stained with 0.1% toluidine blue for 
plaque counting. For HSV-1, BHK21 cells were incubated (45 min at 37oC) in 
suspension with 10-fold dilutions of virus before supplementation with 1% 
carboxymethylcellulose. After 1-2 days, cells were fixed in 10% formaldehyde and 
stained with 0.1% toluidine blue for plaque counting. For IAV titration, Madin Darby 
canine kidney (MDCK) cell monolayers were incubated (1 h at 37oC) with virus in 
serum-free medium then overlaid with 1.2% Avicel® (IMCD)/DMEM plus 1µg/ml 
TPCK-trypsin (Worthington Biochemical), 0.14% BSA (Sigma) and 1X Glutamax 
(Life Technologies). After 2 days, cells were fixed in 10% formaldehyde and stained 
with 0.1% toluidine blue for plaque counting. Additionally, single-cycle growth 
curves were performed as follows: Parallel cell cultures were infected with WT IAV 
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(MOI = 5 pfu/cell; 37oC) and after 1 h any remaining input virus was removed by acid 
washing (40 mM citric acid, pH 3, 135 mM NaCl, 10 mM KCl). At stated times post-
infection, cultures were harvested and stored at -80oC. The amount of infectious virus 
produced within the time stated was determined by plaque assay as above.  
 
Correlation of viral bioluminescence and infectious particle production 
To correlate M3:luciferase MuHV-4 (M3:luc MuHV-4) and CMV:luciferase HSV-1 
(CMV:luc HSV-1) bioluminescence with production of infectious particles, parallel 
confluent fibroblast monolayers were incubated with luciferase viruses at a range of 
multiplicities of infection (MOI; 2 - 0.001 p.f.u./cell for M3:luc MuHV-4; 10 – 0.001 
p.f.u./cell for CMV:luc HSV-1). Input virus was then removed by acid washing (40 
mM citric acid, pH 3, 135 mM NaCl, 10 mM KCl). Bioluminescence was monitored 
in real-time using a Lumicycle-32 (Actimetrics). At stated times post-infection, 
parallel cultures were harvested and stored at -80oC. The amount of infectious virus 
produced was determined by plaque assay. The total bioluminescence acquired during 
stated times post-infection was determined by the area under curve (AUC) method. 
Correlation analysis was performed using linear regression (Total bioluminescence 
vs. Log10 (p.f.u.) produced by equivalent cultures over the same time frame during 
exponential growth).  
 
ICP0 in vitro expression assay  
Infected Cell Polypeptide 0 (ICP0) adenoviral vectors were a kind gift from Anna 
Salvetti and Marie-Claude Geoffroy (INSERM U649, Nantes, France). This Tet-On 
system comprises Ad.CMV.rtTA (expressing rtTA from the HCMV immediate early 
promoter), Ad.TRE.ICP0 (expressing ICP0 from a Tetracycline-Responsive (TRE) 
promoter) and Ad.TRE.FXE (expressing a non-functional RING-finger deletion 
mutant (FXE) of ICP0 from a TRE promoter) as previously described (48). NIH3T3 
cells expressing the Bmal1:luc reporter construct were infected with the adenovirus 
vectors alone or in combination (Ad.CMV.rtTA: MOI = 10 pfu/cell; Ad.TRE.ICP0 or 
Ad.TRE.FXE: MOI = 4 pfu/cell). After 46 h of bioluminescence recording, 
doxycycline (Dox) was added (1 µg/ml) and bioluminescence recording resumed.  
 
Proteomics: Lysis and alkylation  
Primary fibroblasts from wild type (WT; Bmal1+/+) and Bmal1-/- mice were grown to 
confluence in 6-well plates (n=3 per time point) and synchronized with 100 nM 
dexamethasone for 20 minutes, their medium exchanged, and then incubated under 
constant conditions (37oC in darkness). Cells were then harvested by briefly washing 
with ice-cold PBS and incubating with lysis buffer (250 mM HEPES, 1% SDS, 1% 
NP-40, 10 mM DTPA) for 20 minutes. The first time-point was designated Circadian 
Time (CT) 18, and the other CT30 based on the assessment of cells expressing the 
Bmal1:luc or the Per2:luc reporter that were synchronized in parallel (see Fig. 3C and 
Fig. 4C). After scraping the cell monolayers into 1.5ml tubes, lysates were pre-cleared 
by centrifugation at 16,100 rpm in a bench top microfuge for 10 minutes at 4°C. 
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Protein concentration was determined using the BCA Protein Assay Kit (Thermo 
Pierce) and 100 µg per condition transferred into a new tube. The final volume was 
adjusted to 100µl with lysis buffer. The samples were then reduced with 5 µl of 200 
mM TCEP and incubated at 55°C for 1 h. 5 µl of 375 mM iodoacetamide was added 
to alkylate proteins and incubated for 30 minutes, protected from light, at room 
temperature. The alkylation reaction was quenched by adding 600 µl of ice-cold 
acetone and protein precipitated by incubating at -20°C overnight. On the following 
day, the samples were centrifuged at 16,100 rpm in a bench top microfuge for 15 
minutes at 4°C. Acetone was removed and the pellets air-dried for 5 minutes at room 
temperature. 
  
Proteomics: Digestion and tandem mass tag (TMT) labelling  
Acetone-precipitated pellets were resuspended in 100 µl of 100mM TEAB aided by 
sonication on ice for 10 cycles (30 seconds on; 30 seconds off; medium power) in a 
Bioruptor sonicator. Trypsin (2.5 µg Promega Trypsin Gold) per 100 µg protein 
sample, and incubated for 1 h at 37°C. After the initial incubation a further 2.5 µg 
trypsin was added and the digestion allowed to proceed overnight at 37°C. TMT 
labelling was performed according to the manufacturer’s instructions (Thermo). 
Briefly, the TMT labelling reagents were resuspended by adding 82 µl anhydrous 
acetonitrile (ACN) to each vial. Then, 41 µl of the TMT reagent was added to the 
digested proteins and incubated for 1 h at room temperature with occasional 
vortexing. 8 µl of 5% hydroxylamine was then added to the samples and incubated for 
15 minutes at room temperature to quench the reaction. TMT-labelled samples were 
combined after elution at equimolar ratios (as below) and dried by vacuum 
centrifugation. 
 
Wild type: CT18 vs. CT30 
TMT label   Time point 
126 Wild type CT30 Rep A 
127 Wild type CT30 Rep B 
128 Wild type CT30 Rep C 
129 Wild type CT18 Rep A 
130 Wild type CT18 Rep B 
131 Wild type CT18 Rep C 
 
Bmal1–/– CT18 vs. CT30 
TMT label   Time point 
126 Bmal1–/– CT18 Rep A 
127 Bmal1–/– CT18 Rep B 
128 Bmal1–/– CT18 Rep C 
129 Bmal1–/– CT30 Rep A 
130 Bmal1–/– CT30 Rep B 
131 Bmal1–/– CT30 Rep C 
 
 
15 
 
Proteomics: Clean-up and LC-MS/MS analysis  
Peptides dried by vacuum centrifugation were cleaned up in preparation for LC-
MS/MS analysis using C18 Stage Tips with a centrifuge-based protocol. Peptides 
were then aliquoted and taken to dryness by vacuum centrifugation and may be stored 
at -80°C until required for LC-MS/MS analysis. Labelled peptide samples were 
resuspended in 50µl 0.1% TFA, sonicated for 15 minutes and injected (5µl per 
injection). Peptide mixtures were separated on a 50 cm, 75um I.D. Pepmap column 
over a 3 h gradient at 40°C and eluted directly into the mass spectrometer (Thermo Q 
Exactive Orbitrap). Xcalibur software was used to control the data acquisition. The 
instrument was run in data dependent acquisition mode with the top 10 most abundant 
peptides selected for tandem mass spectrometry (MS/MS) by higher energy 
collisional dissociation (HCD) fragmentation techniques. MS spectra were acquired at 
a resolution of 70,000 and an ion target of 3x106. HCD scans were performed with 
35% normalised collision energy (NCE) at 35,000 resolution (at m/z 200), and the ion 
target set to 2x105 so as to avoid coalescence. 
 
Proteomics: Data analysis  
MaxQuant v1.5.2.8 was used to process the raw data acquired with a reporter ion 
quantification method. The Uniprot KB database of mouse sequences was used for 
peptide identification. Peptides identified with confidence interval (CI) values above 
95% were used for protein identification and quantification. Database searching 
parameters included precursor ion mass tolerance of 5 ppm and fragment mass 
tolerance of 0.02 Da, digestion by trypsin, TMT 6-plex modification of peptide N-
termini and lysine residues, with dynamic modifications at oxidation (M), 
deamination (N,Q), in addition to the static modifications at Methylthio (C). A 
peptide estimated false discovery rate (FDR) of 0.1% was used to generate tables with 
protein and peptide identifications and quantifications. Feature matching was enabled 
between runs for peptide identification. Reporter ion intensity (corrected and 
uncorrected) was imported into Perseus v1.5.2.6 for statistical analysis. Summary 
statistics were calculated on log2 transformed reporter ion intensities. Data quality 
obtained from the TMT-based quantitative proteomics analysis was checked by S-
curve analysis, and polygon and volcano plots. Corrected intensities were normalised 
by subtracting the mean value for each reporter ion column from each intensity within 
that column. Histograms revealed normal distributions centred on zero, confirming 
that this transformation was successful. To compare values more easily, data for each 
protein was normalised by the z-score method across all time-points and genotypes. 
These values were then used for subsequent analysis. Two-tailed t-tests were 
performed in Perseus using a false discovery rate (FDR) cut-off of 0.05 and a within 
groups variance S0 factor of 0.1. FDR was calculated by permutation-based method 
using n=250 permutations per test. Proteins showing significant difference between 
CT18 and CT30 in WT cells, but not Bmal1-/- cells, were subsequently tested via two-
tailed t-test for significant differences between WT and Bmal1-/- cells at both CT18 
and CT30 (FDR cut-off 0.05) and presented graphically in R using the HeatMap 
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package (See Fig. S7). Proteins meeting both significance criteria were then subject to 
DAVID Functional Annotation Clustering analysis (See Table S1 and Table S2). 
Outputs were graphically presented using Cytoscape EnrichmentMap application and 
annotated using Clustermaker Markov Cluster Algorithm and WordCloud.  
 
Statistical analysis 
For animal experiments, two-way analysis of variance (ANOVA) was performed on 
Log10-transformed values. Normality and equality of variance were confirmed by the 
Kolmogorov-Smirnov test and Levene’s median test respectively. Multiple two-tailed 
t-tests with FDR cut-off of 0.05 were also performed (*P<0.05, **P<0.01, 
***P<0.001). For cellular assays with multiple groups, ANOVA was performed with 
Holm-Sidak correction for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). 
Equality of variance was confirmed via Brown-Forsythe test. For cellular assays with 
two groups, two-tailed t-tests with Welch’s correction were performed. F-tests were 
used to compare variances and variances were not significantly different unless stated. 
For luciferase herpesvirus cellular assays, raw bioluminescence values were 
background-subtracted (bioluminescence – bioluminescence at t = 0h post-infection) 
and total bioluminescence calculated using the area under curve (AUC) method. For 
each experiment, total bioluminescence values were normalized (0% = 
bioluminescence at t = 0-1h; 100% = maximum total bioluminescence value). For 
analysis of virus replication kinetic parameters (Hill slope, time to 50% peak 
infection, and time to 50% decrease from peak infection), raw bioluminescence values 
were subject to asymmetric sigmoidal non-linear regression as illustrated in Fig. 3B, 
with goodness of fit reported by the coefficient of determination, R2. Pearson’s 
analysis was performed to test for correlations, with the correlation coefficient (r) and 
two-tailed P values reported. PB2::GLUC IAV cellular assays, raw bioluminescence 
values were background-subtracted (PB2::LUC-infected bioluminescence – mock-
infected bioluminescence). Values were subject to sigmoidal dose-response (variable 
slope) non-linear regression to determine plateau bioluminescence, with goodness of 
fit reported by R2. Total IAV PB2::GLuc bioluminescence was calculated using the 
area under curve (AUC) method.  
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Gene Ontology Term Gene IDs Fold Enrichment P = 
Enrichment Score:  7.333    
Endoplasmic reticulum part RAB2B, FKBP9, ERP29, PDIA6, PDIA4, CALU, STT3A, P4HA2, 
P4HA1, TXNDC5, SEC22B, ASPH, FKBP10, SSR3, RCN2 
7.88 5.13E-09 
Endoplasmic reticulum 
lumen 
FKBP9, P4HA2, P4HA1, TXNDC5, ERP29, PDIA6, PDIA4, 
FKBP10, RCN2, CALU 
16.86 6.22E-09 
Endoplasmic reticulum RAB2A, RAB2B, FKBP9, CKAP4, ERP29, PDIA6, PDIA4, 
SRPRB, ALDH3A2, CALU, SCFD1, STT3A, LEPRE1, P4HA2, 
P4HA1, TXNDC5, SEC22B, ASPH, FKBP10, RAB21, RCN2, 
SSR3 
3.19 3.15E-06 
Enrichment Score: 7.235    
Translation RPSA, CARS, RPL13, SARS, GM8730, AARS, EIF2A, EEF2, 
RPS2, RPS4X, RPS8, RPS7, RPS3, GM10653, EIF4G2, RPL7, 
GM6576, RPL18A, EIF3H, RPLP0, RPL21, RPS12, RPL3, 
EIF3L, TPR 
8.91 6.66E-15 
Structural constituent of 
ribosome 
RPSA, RPL13, GM8730, RPS2, RPS4X, RPS8, RPS3, RPS7, 
GM10653, GM6576, RPL18A, RPL7, RPL21, RPLP0, RPS12, 
RPL3 
11.62 1.78E-10 
Ribonucleoprotein complex RPSA, RPL13, NHP2L1, SNRPD3, GM8730, EEF2, SRPRB, 
RPS2, RPS4X, RPS8, RPS7, RPS3, GM10653, PA2G4, RPL7, 
GM6576, RPL18A, RPLP0, SRRM2, RPL21, RPS12, RPL3, 
SRP72 
5.52 7.52E-10 
Ribosome RPSA, RPL13, GM8730, RPS2, RPS4X, RPS8, RPS3, RPS7, 
GM10653, GM6576, RPL18A, RPL7, RPL21, RPLP0, RPS12, 
RPL3 
8.85 4.97E-09 
Structural molecule activity RPSA, RPL13, GM8730, COL3A1, RPS2, RPS4X, COL5A2, 
RPS8, RPS7, RPS3, GM10653, COPB2, RPL7, GM6576, 
RPL18A, RPL21, RPLP0, RPS12, COL1A2, RPL3, TUBB6 
5.29 1.30E-08 
Small ribosomal subunit GM10653, RPSA, GM6576, RPS4X, RPS2, RPS3 20.93 8.47E-05 
Non-membrane-bounded 
organelle 
DYNC1LI2, RPL13, NHP2L1, CAPZA2, TCOF1, RPS2, RPS3, 
MYL9, GM10653, AKT1, PFN2, SORBS3, RPL7, GM6576, 
RPLP0, RPL3, EIF3L, H2AFY, TUBB6, DDX21, RPSA, TCP1, 
GM8730, RPS4X, RPS8, FARP1, RPS7, PA2G4, RPL18A, 
RPL21, RPS12, SRP72, WDR1, MAPRE1 
2.02 8.96E-05 
Ribosomal subunit GM10653, RPSA, RPL7, GM6576, RPS4X, RPS2, RPS3 11.04 1.97E-04 
Enrichment Score: 5.729    
Endoplasmic reticulum 
lumen 
FKBP9, P4HA2, P4HA1, TXNDC5, ERP29, PDIA6, PDIA4, 
FKBP10, RCN2, CALU 
16.86 6.22E-09 
Intracellular organelle lumen FKBP9, NHP2L1, TCOF1, PDIA6, PDIA4, CALU, GOT2, P4HA2, 
P4HA1, SRRM2, EIF3L, DDX21, ACADM, ERP29, ACADL, 
RBBP7, PA2G4, C1QBP, TXNDC5, SRP72, HSPD1, RBM14, 
FKBP10, MDH2, RCN2 
2.68 1.01E-05 
Enrichment Score: 3.707    
Glutamine family amino acid 
metabolic process 
GOT2, ALDH18A1, GFPT1, PHGDH, ASNS, CAD 17.24 2.29E-05 
Amine biosynthetic process GOT2, ALDH18A1, MAT2A, SRM, PHGDH, ASNS, PSAT1 11.85 2.55E-05 
Cellular amino acid 
biosynthetic process 
GOT2, ALDH18A1, MAT2A, PHGDH, ASNS, PSAT1 16.84 2.56E-05 
Carboxylic acid biosynthetic 
process 
GOT2, PTGES3, ALDH18A1, MAT2A, PHGDH, ASNS, GSTO1, 
PSAT1 
7.01 1.38E-04 
Nitrogen compound 
biosynthetic process 
GOT2, ALDH18A1, MAT2A, SRM, ATP5B, PHGDH, ASNS, 
CAD, PSAT1 
3.68 2.96E-03 
Aspartate family amino acid 
metabolic process 
GOT2, PHGDH, ASNS 16.84 1.33E-02 
Enrichment Score: 3.484    
Pigment granule RAB2A, LAMP1, ERP29, TMED10, SEC22B, PDIA6, PDIA4, 
CALU 
11.43 5.73E-06 
Melanosome RAB2A, LAMP1, ERP29, TMED10, SEC22B, PDIA6, PDIA4, 
CALU 
11.43 5.73E-06 
Cytoplasmic membrane-
bounded vesicle 
RAB2A, COPZ2, CAPZA2, ERP29, ESD, PDIA6, PDIA4, CALU, 
COPB2, LAMP1, TMED10, SEC22B, VAMP2, HSPD1, RAB21 
4.40 6.37E-06 
Cytoplasmic vesicle RAB2A, COPZ2, CAPZA2, ERP29, ESD, PDIA6, PDIA4, CALU, 
COPB2, LAMP1, TMED10, SEC22B, VAMP3, VAMP2, HSPD1, 
RAB21 
3.82 1.48E-05 
Endomembrane system COPZ2, RAB2B, CAPZA2, CLIC1, MAN2A1, COPB2, STT3A, 
TMED10, SEC22B, VAMP2, ASPH, TPR, RAB21, SSR3 
3.18 3.97E-04 
Cytoplasmic vesicle 
membrane 
COPZ2, COPB2, CAPZA2, TMED10, VAMP2, RAB21 8.37 7.12E-04 
Golgi apparatus part COPZ2, COPB2, RAB2B, MAN2A1, TMED10, SEC22B, 
VAMP2, RAB21 
4.28 2.54E-03 
Golgi apparatus COPZ2, RAB2A, COPB2, RAB2B, MAN2A1, SCFD1, ARF4, 
TMED10, SEC22B, VAMP2, MAPRE1, RAB21 
2.14 2.30E-02 
Enrichment Score: 3.081    
Protein folding FKBP9, CCT5, TCP1, FKBP5, FKBP4, AARS, HSPD1, FKBP10 7.78 7.14E-05 
Peptidyl-prolyl cis-trans 
isomerase activity 
FKBP9, FKBP5, FKBP4, FKBP10 14.33 2.61E-03 
Enrichment Score: 2.076    
Endomembrane system COPZ2, RAB2B, CAPZA2, CLIC1, MAN2A1, COPB2, STT3A, 
TMED10, SEC22B, VAMP2, ASPH, TPR, RAB21, SSR3 
3.18 3.97E-04 
Nuclear envelope-ER 
network 
RAB2B, STT3A, SEC22B, ASPH, SSR3 3.79 4.18E-02 
Enrichment Score: 1.969    
Procollagen-proline 
dioxygenase activity 
LEPRE1, P4HA2, P4HA1 53.73 1.27E-03 
Peptidyl-proline dioxygenase 
activity 
LEPRE1, P4HA2, P4HA1 53.73 1.27E-03 
Oxidoreductase activity 
(paired donors) 
LEPRE1, P4HA2, P4HA1, ASPH 16.71 1.67E-03 
L-ascorbic acid binding LEPRE1, P4HA2, P4HA1 18.80 1.07E-02 
Vitamin binding GOT2, LEPRE1, P4HA2, P4HA1, PSAT1 5.18 1.55E-02 
Carboxylic acid binding LEPRE1, P4HA2, P4HA1, CAD 5.90 2.97E-02 
Enrichment Score: 1.946    
tRNA aminoacylation for 
protein translation 
CARS, SARS, AARS, TPR 10.74 5.93E-03 
tRNA aminoacylation CARS, SARS, AARS, TPR 10.74 5.93E-03 
Amino acid activation CARS, SARS, AARS, TPR 10.74 5.93E-03 
Ligase activity (aminoacyl-
tRNA) 
CARS, SARS, AARS, TPR 10.45 6.41E-03 
Enrichment Score: 1.903    
Endomembrane system COPZ2, RAB2B, CAPZA2, CLIC1, MAN2A1, COPB2, STT3A, 
TMED10, SEC22B, VAMP2, ASPH, TPR, RAB21, SSR3 
3.18 3.97E-04 
Golgi apparatus part COPZ2, COPB2, RAB2B, MAN2A1, TMED10, SEC22B, 
VAMP2, RAB21 
4.28 2.54E-03 
Golgi membrane COPZ2, COPB2, RAB2B, MAN2A1, SEC22B, RAB21 5.32 5.23E-03 
Protein transport RAB2A, COPZ2, RAB2B, ERP29, COPB2, SCFD1, ARF4, 
TMED10, SEC22B, SRP72, TPR, RAB21, SSR3 
2.47 5.91E-03 
Protein localization RAB2A, COPZ2, RAB2B, ERP29, COPB2, SCFD1, ARF4, 
TMED10, SEC22B, SRP72, TPR, GNB2L1, RAB21, SSR3 
2.30 7.19E-03 
Vesicle-mediated transport COPZ2, RAB2A, COPB2, RAB2B, SCFD1, ARF4, TMED10, 
SEC22B, VAMP3, VAMP2 
2.65 1.26E-02 
Golgi apparatus COPZ2, RAB2A, COPB2, RAB2B, MAN2A1, SCFD1, ARF4, 
TMED10, SEC22B, VAMP2, MAPRE1, RAB21 
2.14 2.30E-02 
Intracellular protein transport COPZ2, RAB2A, COPB2, TMED10, SRP72, TPR, SSR3 3.13 2.37E-02 
Enrichment Score: 1.597    
Cofactor binding GOT2, ACADM, PHGDH, ACADL, PSAT1, IDH3A, MDH1 3.88 9.02E-03 
Coenzyme binding ACADM, PHGDH, ACADL, IDH3A, MDH1 3.92 3.80E-02 
NAD or NADH binding PHGDH, IDH3A, MDH1 8.55 4.72E-02 
Enrichment Score: 1.596    
Nucleotide binding DYNC1LI2, ALDH18A1, ATP5B, FKBP4, ASNS, CAD, AKT1, 
UBE2D3, TUBB6, DDX21, TPR, RAB21, RAB2A, RAB2B, 
CARS, TCP1, ACADM, MAT2A, SARS, AARS, EEF2, SRPRB, 
ACADL, IDH3A, CCT5, ARF4, PHGDH, HSPD1, RBM14, MDH1 
1.72 2.56E-03 
Purine nucleotide binding DYNC1LI2, ALDH18A1, ATP5B, FKBP4, ASNS, CAD, AKT1, 
UBE2D3, TUBB6, DDX21, TPR, RAB21, RAB2A, RAB2B, 
CARS, TCP1, ACADM, MAT2A, SARS, AARS, EEF2, SRPRB, 
ACADL, CCT5, ARF4, HSPD1 
1.74 5.06E-03 
Ribonucleotide binding RAB2A, RAB2B, TCP1, CARS, DYNC1LI2, ALDH18A1, MAT2A, 
SARS, ATP5B, FKBP4, AARS, ASNS, CAD, EEF2, SRPRB, 
AKT1, UBE2D3, CCT5, ARF4, TUBB6, DDX21, HSPD1, TPR, 
RAB21 
1.68 1.20E-02 
Enrichment Score: 1.591    
Organelle membrane COPZ2, RAB2B, ALDH18A1, ATP5B, CAPZA2, ALDH3A2, 
GOT2, COPB2, MAN2A1, STT3A, TMED10, SEC22B, 
SLC25A1, VAMP2, HSPD1, ASPH, RAB21, MDH2, SSR3 
2.85 8.52E-05 
Mitochondrial matrix GOT2, ACADM, C1QBP, HSPD1, ACADL, MDH2 4.47 1.07E-02 
Mitochondrial part GOT2, ACADM, ALDH18A1, C1QBP, ATP5B, SLC25A1, 
HSPD1, ACADL, ALDH3A2, MDH2 
2.32 2.71E-02 
Mitochondrial inner 
membrane 
GOT2, ALDH18A1, ATP5B, SLC25A1, HSPD1, ALDH3A2, 
MDH2 
2.87 3.40E-02 
Enrichment Score: 1.458    
Collagen COL3A1, COL1A2, LOX, COL5A2 25.56 4.64E-04 
Collagen fibril organization P4HA1, COL3A1, LOX, COL5A2 23.53 6.01E-04 
SMAD binding COL3A1, COL1A2, COL5A2 18.80 1.07E-02 
Extracellular matrix 
structural constituent 
COL3A1, COL1A2, COL5A2 12.54 2.33E-02 
Enrichment Score: 1.404    
Energy derivation by 
oxidation 
PTGES3, AKT1, IDH3A, MDH2, MDH1 6.30 7.95E-03 
Tricarboxylic acid cycle IDH3A, MDH2, MDH1 16.11 1.45E-02 
Acetyl-CoA catabolic 
process 
IDH3A, MDH2, MDH1 15.44 1.57E-02 
Aerobic respiration IDH3A, MDH2, MDH1 13.73 1.96E-02 
Coenzyme catabolic process IDH3A, MDH2, MDH1 12.78 2.25E-02 
Acetyl-CoA metabolic 
process 
IDH3A, MDH2, MDH1 11.95 2.55E-02 
Cofactor catabolic process IDH3A, MDH2, MDH1 11.58 2.70E-02 
Enrichment Score: 1.363    
Energy derivation  PTGES3, AKT1, IDH3A, MDH2, MDH1 6.30 7.95E-03 
Hexose metabolic process PTGES3, AKT1, MAN2A1, MDH2, MDH1 3.65 4.70E-02 
Enrichment Score: 1.332    
Vesicle-mediated transport COPZ2, RAB2A, COPB2, RAB2B, SCFD1, ARF4, TMED10, 
SEC22B, VAMP3, VAMP2 
2.65 1.26E-02 
Exocytosis SCFD1, TMED10, VAMP3, VAMP2 4.49 5.85E-02 
Enrichment Score: 1.109    
GTP binding RAB2A, RAB2B, FKBP4, ARF4, TUBB6, EEF2, SRPRB, RAB21 2.83 2.21E-02 
guanyl nucleotide binding RAB2A, RAB2B, FKBP4, ARF4, TUBB6, EEF2, SRPRB, RAB21 2.76 2.49E-02 
guanyl ribonucleotide 
binding 
RAB2A, RAB2B, FKBP4, ARF4, TUBB6, EEF2, SRPRB, RAB21 2.76 2.49E-02 
Enrichment Score: 0.089    
Regulation of translation AKT1, EIF4G2, PA2G4, EIF2A 4.94 4.64E-02 
 
Gene Ontology Term Gene IDs Fold Enrichment P = 
Enrichment Score: 2.235       
Hydrogen ion 
transmembrane 
transporter activity 
UQCRH, COX6B1, ATP6V1H, ATP5A1, COX5A 22.51 6.10E-05 
Generation of precursor 
metabolites and energy NDUFB11, IDH3G, UQCRH, ATP6V1H, ATP5A1 7.44 3.92E-03 
Mitochondrial inner 
membrane NDUFB11, UQCRH, COX6B1, ATP5A1, COX5A 6.81 5.19E-03 
Oxidative phosphorylation UQCRH, ATP6V1H, ATP5A1 20.80 8.60E-03 
Mitochondrial membrane NDUFB11, UQCRH, COX6B1, ATP5A1, COX5A 5.48 1.10E-02 
Mitochondrial envelope NDUFB11, UQCRH, COX6B1, ATP5A1, COX5A 5.16 1.36E-02 
Organelle membrane NDUFB11, UQCRH, COX6B1, ATP6V1H, ATP5A1, COX5A 2.99 4.15E-02 
Enrichment Score: 2.219       
Nucleosome HIST1H2AB, HIST1H2AA, HIST1H2AF, HIST1H2AD, HIST1H2AH, HIST3H2A 26.02 4.28E-04 
Protein-DNA complex HIST1H2AB, HIST1H2AA, HIST1H2AF, HIST1H2AD, HIST1H2AH, HIST3H2A 21.51 7.49E-04 
Nucleosome assembly HIST1H2AB, HIST1H2AA, HIST1H2AF, HIST1H2AD, HIST1H2AH, HIST3H2A 21.27 7.90E-04 
Chromatin assembly HIST1H2AB, HIST1H2AA, HIST1H2AF, HIST1H2AD, HIST1H2AH, HIST3H2A 20.71 8.55E-04 
DNA packaging HIST1H2AB, HIST1H2AA, HIST1H2AF, HIST1H2AD, HIST1H2AH, HIST3H2A 15.38 2.02E-03 
Cellular macromolecular 
complex subunit 
organization 
HIST1H2AB, HIST1H2AA, HIST1H2AF, HIST1H2AD, 
HIST1H2AH, HIST3H2A, STMN1 7.92 3.13E-03 
Chromosome HIST1H2AB, HMGB2, HIST1H2AA, HIST1H2AF, HIST1H2AD, HIST1H2AH, HIST3H2A 5.34 1.21E-02 
Enrichment Score: 2.012       
Lamellipodium DBNL, WASF2, ABI2, ABI1 25.61 4.49E-04 
Cell leading edge DBNL, WASF2, ABI2, ABI1 14.41 2.38E-03 
Cytoskeleton DBNL, UTRN, WASF2, ABI2, ABI1, MARCKS, STMN1, TPM1 2.88 1.49E-02 
Cell projection DBNL, UTRN, WASF2, ABI2, ABI1 3.51 4.70E-02 
Enrichment Score: 1.834       
Non-membrane-bounded 
organelle 
HIST1H2AB, DBNL, HMGB2, HIST1H2AA, HIST1H2AF, 
HIST1H2AD, WASF2, UTRN, ABI2, GM5218, ABI1, TPM1, 
RPL29, HIST1H2AH, GM10709, MARCKS, HIST3H2A, 
STMN1 
2.94 2.30E-04 
Cytoskeletal protein 
binding DBNL, UTRN, WASF2, MARCKS, STMN1, TPM1 5.35 4.30E-03 
Actin binding DBNL, UTRN, WASF2, MARCKS, TPM1 6.41 6.67E-03 
Cytoskeleton DBNL, UTRN, WASF2, ABI2, ABI1, MARCKS, STMN1, TPM1 2.88 1.49E-02 
Cell cortex DBNL, UTRN, MARCKS 9.60 3.65E-02 
Enrichment Score: 1.494       
Oxidative phosphorylation UQCRH, ATP6V1H, ATP5A1 20.80 8.60E-03 
Phosphorylation GALK1, UQCRH, ABI2, ATP6V1H, ABI1, ATP5A1 3.24 3.17E-02 
Enrichment Score: 0.536       
Oxidation reduction CYB5R1, NDUFB11, IDH3G, UQCRH, AOC2, AOC3 3.47 2.47E-02 
 
